This content is machine translated Colon Cancer New therapeutic perspectives raise hope for improved overall survival This year’s ASCO brought exciting study results to light. Especially in tumors of the upper and lower gastrointestinal tract, there were developments, some of which had practice-changing potential. In metastatic colon cancer,…
View Post 4 min This content is machine translated Metastatic colorectal cancer Comparison between bevacizumab and cetuximab in KRAS exon2 wild type. According to preliminary results of a large phase III trial presented at this year’s ASCO congress, bevacizumab and cetuximab (combined with FOLFOX or FOLFIRI) show similar efficacy in terms of…
View Post 6 min This content is machine translated Interview at ASCO GI on new data from the OPUS study. “We are a good step closer to personalized therapy in mCRC” In the treatment of metastatic colorectal cancer, there were new results on subgroup analyses of the OPUS trial at this year’s ASCO GI in San Francisco. As previously shown in…
View Post 4 min This content is machine translated 1st Swiss Symposium Peritoneal Malignancies and HIPEC Enabling individualized treatment At the first Swiss symposium on peritoneal malignancies and HIPEC in St. Gallen, experts spoke on the topics of ovarian cancer and metastatic colorectal cancer. It was about current and…
View Post 4 min This content is machine translated Treatment of metastatic colorectal carcinoma. Patients with RAS wild type benefit in overall survival New data on first-line treatment of metastatic colorectal cancer were presented at the ASCO GI in San Francisco. The post-hoc analyses consistently confirm that RAS mutation status is an important…
